Search

Your search keyword '"Allanore Yannick"' showing total 2,128 results
Start Over Author "Allanore Yannick"
2,128 results on '"Allanore Yannick"'

1. Lysophosphatidic acid receptor 1 inhibition: a potential treatment target for pulmonary fibrosis.

Author

Volkmann, Elizabeth, Denton, Christopher, Kolb, Martin, Wijsenbeek-Lourens, Marlies, Emson, Claire, Hudson, Krischan, Amatucci, Anthony, Distler, Oliver, Allanore, Yannick, and Khanna, Dinesh

Subjects
Humans, Receptors, Lysophosphatidic Acid, Animals, Signal Transduction, Phosphoric Diester Hydrolases, Idiopathic Pulmonary Fibrosis, Molecular Targeted Therapy, Lung, Antifibrotic Agents, Lysophospholipids, Treatment Outcome, Pulmonary Fibrosis, Phosphodiesterase Inhibitors
Abstract

Lysophosphatidic acid (LPA)-mediated activation of LPA receptor 1 (LPAR1) contributes to the pathophysiology of fibrotic diseases such as idiopathic pulmonary fibrosis (IPF) and systemic sclerosis (SSc). These diseases are associated with high morbidity and mortality despite current treatment options. The LPA-producing enzyme autotaxin (ATX) and LPAR1 activation contribute to inflammation and mechanisms underlying fibrosis in preclinical fibrotic models. Additionally, elevated levels of LPA have been detected in bronchoalveolar lavage fluid from patients with IPF and in serum from patients with SSc. Thus, ATX and LPAR1 have gained considerable interest as pharmaceutical targets to combat fibrotic disease and inhibitors of these targets have been investigated in clinical trials for IPF and SSc. The goals of this review are to summarise the current literature on ATX and LPAR1 signalling in pulmonary fibrosis and to help differentiate the novel inhibitors in development. The mechanisms of action of ATX and LPAR1 inhibitors are described and preclinical studies and clinical trials of these agents are outlined. Because of their contribution to numerous physiologic events underlying fibrotic disease, ATX and LPAR1 inhibition presents a promising therapeutic strategy for IPF, SSc and other fibrotic diseases that may fulfil unmet needs of the current standard of care.

Published
2024

2. Immune-Targeted Therapies in SSc

Author

Ong, Voon H., Allanore, Yannick, Allanore, Yannick, editor, Varga, John, editor, Denton, Christopher P., editor, Kuwana, Masataka, editor, Chung, Lorinda, editor, and Shah, Ami A., editor

Published
2024
Full Text
View/download PDF

4. Tendons, Joints, and Bone

Author

Zanatta, Elisabetta, Buch, Maya H., Allanore, Yannick, Allanore, Yannick, editor, Varga, John, editor, Denton, Christopher P., editor, Kuwana, Masataka, editor, Chung, Lorinda, editor, and Shah, Ami A., editor

Published
2024
Full Text
View/download PDF

6. Genetic Factors

Author

Assassi, Shervin, Martin, Javier, Allanore, Yannick, Allanore, Yannick, editor, Varga, John, editor, Denton, Christopher P., editor, Kuwana, Masataka, editor, Chung, Lorinda, editor, and Shah, Ami A., editor

Published
2024
Full Text
View/download PDF

7. Systemic sclerosis associated interstitial lung disease: a conceptual framework for subclinical, clinical and progressive disease.

Author

Roofeh, David, Brown, Kevin, Kazerooni, Ella, Tashkin, Donald, Assassi, Shervin, Martinez, Fernando, Wells, Athol, Raghu, Ganesh, Denton, Christopher, Chung, Lorinda, Hoffmann-Vold, Anna-Maria, Distler, Oliver, Johannson, Kerri, Allanore, Yannick, Matteson, Eric, Kawano-Dourado, Leticia, Pauling, John, Seibold, James, Volkmann, Elizabeth, Walsh, Simon, Oddis, Chester, White, Eric, Barratt, Shaney, Bernstein, Elana, Domsic, Robyn, Dellaripa, Paul, Conway, Richard, Rosas, Ivan, Bhatt, Nitin, Hsu, Vivien, Ingegnoli, Francesca, Kahaleh, Bashar, Garcha, Puneet, Gupta, Nishant, Khanna, Surabhi, Korsten, Peter, Lin, Celia, Mathai, Stephen, Strand, Vibeke, Doyle, Tracy, Steen, Virginia, Zoz, Donald, Ovalles-Bonilla, Juan, Rodriguez-Pinto, Ignasi, Shenoy, Padmanabha, Lewandoski, Andrew, Belloli, Elizabeth, Lescoat, Alain, Nagaraja, Vivek, Ye, Wen, Huang, Suiyuan, Maher, Toby, and Khanna, Dinesh

Subjects
connective tissue disease interstitial lung disease, systemic sclerosis associated interstitial lung disease subsets, systemic sclerosis interstitial lung disease, Humans, Lung Diseases, Interstitial, Scleroderma, Systemic, Vital Capacity, Tomography, X-Ray Computed, Severity of Illness Index, Lung
Abstract

OBJECTIVES: To establish a framework by which experts define disease subsets in systemic sclerosis associated interstitial lung disease (SSc-ILD). METHODS: A conceptual framework for subclinical, clinical and progressive ILD was provided to 83 experts, asking them to use the framework and classify actual SSc-ILD patients. Each patient profile was designed to be classified by at least four experts in terms of severity and risk of progression at baseline; progression was based on 1-year follow-up data. A consensus was reached if ≥75% of experts agreed. Experts provided information on which items were important in determining classification. RESULTS: Forty-four experts (53%) completed the survey. Consensus was achieved on the dimensions of severity (75%, 60 of 80 profiles), risk of progression (71%, 57 of 80 profiles) and progressive ILD (60%, 24 of 40 profiles). For profiles achieving consensus, most were classified as clinical ILD (92%), low risk (54%) and stable (71%). Severity and disease progression overlapped in terms of framework items that were most influential in classifying patients (forced vital capacity, extent of lung involvement on high resolution chest CT [HRCT]); risk of progression was influenced primarily by disease duration. CONCLUSIONS: Using our proposed conceptual framework, international experts were able to achieve a consensus on classifying SSc-ILD patients along the dimensions of disease severity, risk of progression and progression over time. Experts rely on similar items when classifying disease severity and progression: a combination of spirometry and gas exchange and quantitative HRCT.

Published
2023

8. Real-World Effectiveness and Safety of SDZ ETN, an Etanercept Biosimilar, in Patients with Rheumatic Diseases: Final Results from Multi-Country COMPACT Study

Author

Schmalzing, Marc, Kellner, Herbert, Askari, Ayman, De Toro Santos, Javier, Vazquez Perez-Coleman, Julio Cesar, Foti, Rosario, Jeka, Sławomir, Haraoui, Boulos, Allanore, Yannick, Peichl, Peter, Oehri, Martin, Rahman, Masiur, Furlan, Fabricio, Romero, Elisa, Hachaichi, Sohaib, Both, Charlotte, Brueckmann, Ines, and Sheeran, Tom

Published
2024
Full Text
View/download PDF

9. Effect of nintedanib in patients with systemic sclerosis-associated interstitial lung disease and risk factors for rapid progression.

Author

Khanna, Dinesh, Maher, Toby, Volkmann, Elizabeth, Allanore, Yannick, Smith, Vanessa, Assassi, Shervin, Kreuter, Michael, Hoffmann-Vold, Anna-Maria, Kuwana, Masataka, Stock, Christian, Alves, Margarida, Sambevski, Steven, and Denton, Christopher

Subjects
Autoimmune Diseases, Pulmonary Fibrosis, Scleroderma, Systemic, Therapeutics, Humans, Fibrosis, Lung Diseases, Interstitial, Risk Factors, Scleroderma, Systemic
Abstract

OBJECTIVE: To investigate the rate of decline in forced vital capacity (FVC), and the effect of nintedanib on the rate of decline in FVC, in subjects with systemic sclerosis-associated interstitial lung disease (SSc-ILD) who had risk factors for rapid decline in FVC. METHODS: The SENSCIS trial enrolled subjects with SSc and fibrotic ILD of ≥10% extent on high-resolution CT. The rate of decline in FVC over 52 weeks was analysed in all subjects and in those with early SSc (

Published
2023

10. Dyspnoea and cough in patients with systemic sclerosis-associated interstitial lung disease in the SENSCIS trial.

Author

Volkmann, Elizabeth, Kreuter, Michael, Hoffmann-Vold, Anna, Wijsenbeek, Marlies, Smith, Vanessa, Khanna, Dinesh, Denton, Christopher, Wuyts, Wim, Miede, Corinna, Alves, Margarida, Sambevski, Steven, and Allanore, Yannick

Subjects
connective tissue diseases, nintedanib, systemic scleroderma, vital capacity, Humans, Cough, Lung Diseases, Interstitial, Vital Capacity, Dyspnea, Scleroderma, Systemic, Disease Progression, Treatment Outcome
Abstract

OBJECTIVE: The aim of these analyses was to investigate the rate of decline in forced vital capacity (FVC) in patients with SSc-associated interstitial lung disease (SSc-ILD) with and without cough or dyspnoea in the SENSCIS trial. METHODS: Patients in the SENSCIS trial were randomized to receive nintedanib or placebo. Subgroups with and without cough or dyspnoea at baseline were defined by responses to the St Georges Respiratory Questionnaire. RESULTS: At baseline, 114/575 patients (19.8%) did not have cough and 172/574 patients (30.0%) did not have dyspnoea. In the placebo group, the rate of FVC decline over 52 weeks was similar in patients with and without cough (-95.6 and -83.4 mL/year, respectively) or dyspnoea (-95.8 and -87.7 mL/year, respectively). The effect of nintedanib vs placebo on reducing the rate of FVC decline was numerically more pronounced in patients without than with cough [difference: 74.4 (95% CI -11.1, 159.8) vs 31.5 (-11.1, 74.1)] and without than with dyspnoea [79.8 (9.8, 149.7) vs 25.7 (-19.9, 71.3)], but interaction P-values did not indicate heterogeneity in the treatment effect between these subgroups (P = 0.38 and P = 0.20, respectively). CONCLUSION: In the placebo group of the SENSCIS trial, the rate of FVC decline was similar irrespective of the presence of cough or dyspnoea at baseline. The effect of nintedanib on reducing the rate of FVC decline was numerically more pronounced in patients without than with cough or dyspnoea at baseline, but no statistically significant heterogeneity was observed between the subgroups. TRIAL REGISTRATION: ClinicalTrials.gov, https://clinicaltrials.gov, NCT02597933.

Published
2022

12. Tailoring the treatment of inflammatory rheumatic diseases by a better stratification and characterization of the clinical patient heterogeneity. Findings from a systematic literature review and experts' consensus

Author

Ruscitti, Piero, Allanore, Yannick, Baldini, Chiara, Barilaro, Giuseppe, Bartoloni Bocci, Elena, Bearzi, Pietro, Bellis, Elisa, Berardicurti, Onorina, Biaggi, Alice, Bombardieri, Michele, Cantarini, Luca, Cantatore, Francesco Paolo, Caporali, Roberto, Caso, Francesco, Cervera, Ricard, Ciccia, Francesco, Cipriani, Paola, Chatzis, Loukas, Colafrancesco, Serena, Conti, Fabrizio, Corberi, Erika, Costa, Luisa, Currado, Damiano, Cutolo, Maurizio, D'Angelo, Salvatore, Del Galdo, Francesco, Di Cola, Ilenia, Di Donato, Stefano, Distler, Oliver, D'Onofrio, Bernardo, Doria, Andrea, Fautrel, Bruno, Fasano, Serena, Feist, Eugen, Fisher, Benjamin A., Gabini, Marco, Gandolfo, Saviana, Gatto, Mariele, Genovali, Irene, Gerli, Roberto, Grembiale, Rosa Daniela, Guggino, Giuliana, Hoffmann-Vold, Anna Maria, Iagnocco, Annamaria, Iaquinta, Francesco Salvatore, Liakouli, Vasiliki, Manoussakis, Menelaos N., Marino, Annalisa, Mauro, Daniele, Montecucco, Carlomaurizio, Mosca, Marta, Naty, Saverio, Navarini, Luca, Occhialini, Daniele, Orefice, Valeria, Perosa, Federico, Perricone, Carlo, Pilato, Andrea, Pitzalis, Costantino, Pontarini, Elena, Prete, Marcella, Priori, Roberta, Rivellese, Felice, Sarzi-Puttini, Piercarlo, Scarpa, Raffaele, Sebastiani, Giandomenico, Selmi, Carlo, Shoenfeld, Yehuda, Triolo, Giovanni, Trunfio, Francesca, Yan, Qingran, Tzioufas, Athanasios G., and Giacomelli, Roberto

Published
2024
Full Text
View/download PDF

16. Nintedanib in Patients With Systemic Sclerosis-Associated Interstitial Lung Disease: Subgroup Analyses by Autoantibody Status and Modified Rodnan Skin Thickness Score.

Author

Kuwana, Masataka, Allanore, Yannick, Denton, Christopher, Distler, Jörg, Steen, Virginia, Khanna, Dinesh, Matucci-Cerinic, Marco, Mayes, Maureen, Volkmann, Elizabeth, Miede, Corinna, Gahlemann, Martina, Quaresma, Manuel, Alves, Margarida, and Distler, Oliver

Subjects
Autoantibodies, Disease Progression, Female, Humans, Indoles, Lung Diseases, Interstitial, Male, Protein Kinase Inhibitors, Scleroderma, Systemic, Skin, Treatment Outcome
Abstract

OBJECTIVE: Using data from the SENSCIS trial, these analyses were undertaken to assess the effects of nintedanib versus placebo in subgroups of patients with systemic sclerosis-associated interstitial lung disease (SSc-ILD), based on characteristics previously identified as being associated with the progression of SSc-ILD. METHODS: Patients with SSc-ILD were randomized to receive either nintedanib or placebo, stratified by anti-topoisomerase I antibody (ATA) status. We assessed the rate of decline in forced vital capacity (FVC) (expressed in ml/year) over 52 weeks in subgroups based on baseline ATA status, modified Rodnan skin thickness score (MRSS) ( 0.05), indicating that there was no heterogeneity in the effect of nintedanib versus placebo between these subgroups of patients. CONCLUSION: In patients with SSc-ILD, reduction in the annual rate of decline in FVC among patients receiving nintedanib compared to those receiving placebo was not found to be heterogenous across subgroups based on ATA status, MRSS, or SSc subtype.

Published
2022

19. Non-surgical local treatments of digital ulcers in systemic sclerosis: a systematic literature review

Author

Campochiaro, Corrado, Suliman, Yossra A, Hughes, Michael, Schoones, Jan W, Giuggioli, Dilia, Moinzadeh, Pia, Baron, Murray, Chung, Lorinda, Ross, Laura, Maltez, Nancy, Allanore, Yannick, Denton, Christopher P, Distler, Oliver, Frech, Tracy, Furst, Daniel E, Khanna, Dinesh, Krieg, Thomas, Kuwana, Masataka, Matucci-Cerinic, Marco, Pope, Janet, and Alunno, Alessia

Published
2023
Full Text
View/download PDF

20. Surgical management of digital ulcers in systemic sclerosis: A systematic literature review

Author

Suliman, Yossra A, Campochiaro, Corrado, Hughes, Michael, Schoones, Jan W., Giuggioli, Dilia, Moinzadeh, Pia, Baron, Murray, Chung, Lorinda, Ross, Laura, Maltez, Nancy, Allanore, Yannick, Denton, Christopher P., Distler, Oliver, Frech, Tracy, Furst, Daniel E., Khanna, Dinesh, Krieg, Thomas, Kuwana, Masataka, Matucci-Cerinic, Marco, Pope, Janet, and Alunno, Alessia

Published
2023
Full Text
View/download PDF

21. The phenotype of mixed connective tissue disease patients having associated interstitial lung disease

Author

Boleto, Gonçalo, Reiseter, Silje, Hoffmann-Vold, Anna-Maria, Mirouse, Adrien, Cacoub, Patrice, Matucci-Cerinic, Marco, Silvério-António, Manuel, Fonseca, Joao Eurico, Duarte, Ana Catarina, Pestana Lopes, Jorge, Riccieri, Valeria, Lescoat, Alain, Le Tallec, Erwan, Castellví Barranco, Ivan, Tandaipan, Jose Luis, Airó, Paolo, Kuwana, Masataka, Kavosi, Hoda, Avouac, Jérôme, and Allanore, Yannick

Published
2023
Full Text
View/download PDF

22. Infectious sacroiliitis: a retrospective, multicentre study of 39 adults

Author

Hermet Marion, Minichiello Emeline, Flipo René, Dubost Jean, Allanore Yannick, Ziza Jean, Gaudin Philippe, Thomas Thierry, Dernis Emmanuelle, Glace Baptiste, Regnier Alain, and Soubrier Martin

Subjects
Infectious and parasitic diseases, RC109-216
Abstract

Abstract Background Non-brucellar and non-tuberculous infectious sacroiliitis (ISI) is a rare disease, with misleading clinical signs that delay diagnosis. Most observations are based on isolated case reports or small case series. Our aim was to describe the clinical, bacteriological, and radiological characteristics of ISI, as well as the evolution of these arthritis cases under treatment. Methods This retrospective study included all ISI cases diagnosed between 1995 and 2011 in eight French rheumatology departments. ISI was diagnosed if sacroiliitis was confirmed bacteriologically or, in the absence of pathogenic agents, if clinical, biological, and radiological data was compatible with this diagnosis and evolution was favourable under antibiotic therapy. Results Overall, 39 cases of ISI were identified in adults, comprising 23 women and 16 men, with a mean age at diagnosis of 39.7 ± 18.1 years. The left sacroiliac joint (SI) was affected in 59% of cases, with five cases occurring during the post-partum period. Lumbogluteal pain was the most common symptom (36/39). Manipulations of the SI joint were performed in seven patients and were always painful. Mean score for pain using the visual analogue score was 7.3/10 at admission, while 16 patients were febrile at diagnosis. No risk factor was found for 30.7% of patients. A diagnosis of ISI was only suspected in five cases at admission. The mean time to diagnosis was long, being 43.3 ± 69.1 days on average. Mean C-reactive protein was 149.7 ± 115.3 mg/l, and leukocytosis (leukocytes ≥ 10 G/l) was uncommon (n = 15) (mean level of leukocytes 10.4 ± 3.5 G/l). Radiographs (n = 33) were abnormal in 20 cases, revealing lesions of SI, while an abdominopelvic computed tomography (CT) scan (n = 27) was abnormal in 21 cases, suggesting arthritis of the SI joints in 13 cases (48.1%) and a psoas abscess in eight. Bone scans (n = 14) showed hyperfixation of the SI in 13 cases. Magnetic resonance imaging (MRI) (n = 27), when focused on the SI (n = 25), directed towards the diagnosis to ISI in 25 cases. Pathogenic agents were isolated in 33 cases (84.6%) by means of articular puncture (n = 16), blood culture (n = 14), cytobacteriological examination of urine (n = 2), or puncture of the psoas (n = 1). Gram-positive cocci were the mostly isolated common bacteria, with a predominance of staphylococci (n = 21). The most frequently isolated gram-negative bacillus was Pseudomonas aeruginosa (n = 3). Evolution was favourable in 37 out of 39 patients under prolonged antibiotic therapy (mean duration 3.01 ± 1.21 months). Conclusion Our series confirmed that the clinical manifestations of ISI usually lead to delayed diagnosis. Based on our results, we suggest performing an MRI of the spine and SI in clinical situations characterised by lumbogluteal pain and symptoms of an infectious disease, such as fever.

Published
2012
Full Text
View/download PDF

23. Natural variability in the disease course of SSc-ILD: implications for treatment.

Author

Vonk, Madelon, Walker, Ulrich, Volkmann, Elizabeth, Kreuter, Michael, Johnson, Sindhu, and Allanore, Yannick

Subjects
Humans, Lung, Lung Diseases, Interstitial, Risk Factors, Scleroderma, Systemic, Vital Capacity
Abstract

Interstitial lung disease (ILD) affects approximately 50% of patients with systemic sclerosis (SSc) and is the leading cause of death in SSc. Our objective was to gain insight into the progression of SSc-associated ILD (SSc-ILD). Using data from longitudinal clinical trials and observational studies, we assessed definitions and patterns of progression, risk factors for progression, and implications for treatment. SSc-ILD progression was commonly defined as exceeding specific thresholds of lung function worsening and/or increasing radiographic involvement. One definition used in several studies is decline in forced vital capacity (FVC) of ≥10%, or ≥5-10% plus a decline in diffusing capacity of the lung for carbon monoxide ≥15%. Based on these criteria, 20-30% of patients in observational cohorts develop progressive ILD, starting early in the disease course and progressing at a highly variable rate.Risk factors such as age, FVC, extent of fibrosis and presence of anti-topoisomerase I antibodies can help predict progression of SSc-ILD, though composite risk scores may offer greater predictive power. Whilst the variability of the disease course in SSc-ILD makes risk stratification of patients challenging, the decision to initiate, change or stop treatment should be based on a combination of the current disease state and the speed of progression.

Published
2021

24. Does the Impact of COVID‐19 on Patients With Systemic Sclerosis Change Over Time?

Author

Deibel, Elisabeth, Carreira, Patricia E., Vonk, Madelon, del Papa, Nicoletta, Bečvář, Radim, Guillén‐Del‐Castillo, Alfredo, Campochiaro, Corrado, Poormoghim, Hadi, Liem, Sophie, Lazzaroni, Maria‐Grazia, Giollo, Alessandro, Mekinian, Arsène, de Vries‐Bouwstra, Jeska, De Santis, Maria, Balbir‐Gurman, Alexandra, Mihai, Carina, De Luca, Giacomo, Moiseev, Sergey, Zanatta, Elisabetta, Foti, Rosario, Rednic, Simona, Denton, Christopher, Cutolo, Maurizio, Belloli, Laura, Airo, Paolo, Garzanova, Liudmila, Moroncini, Gianluca, İnanç, Murat, Panopoulos, Stylianos, Tandaipan, Jose‐Luis, Chatelus, Emmanuel, Rosato, Edoardo, Kuwana, Masataka, Yavuz, Sule, Alegre‐Sancho, Juan J., Smith, Vanessa, Szűcs, Gabriella, Henes, Joerg, Rodríguez‐Pintó, Ignasi, Atzeni, Fabiola, Spierings, Julia, Truchetet, Marie‐Elise, Milchert, Marcin, Brito de Araujo, Daniel, Riemekasten, Gabriela, Bernardino, Vera, Martin, Thierry, del Galdo, Francesco, Vacca, Alessandra, Mendoza, Fabian, Midtvedt, Øyvind, Murdaca, Giuseppe, Santiago, Tânia, Codullo, Veronica, Cacciapaglia, Fabio, Walker, Ulrich, Brunborg, Cathrine, Tirelli, Francesca, Allanore, Yannick, Furst, Daniel E., Matucci, Marco, Gabrielli, Armando, Distler, Oliver, and Hoffmann‐Vold, Anna‐Maria

Published
2024
Full Text
View/download PDF

25. Riociguat in patients with early diffuse cutaneous systemic sclerosis (RISE-SSc): open-label, long-term extension of a phase 2b, randomised, placebo-controlled trial

Author

Distler, Oliver, Allanore, Yannick, Denton, Christopher P, Kuwana, Masataka, Matucci-Cerinic, Marco, Pope, Janet E, Atsumi, Tatsuya, Bečvář, Radim, Czirják, László, Hachulla, Eric, Ishii, Tomonori, Ishikawa, Osamu, Johnson, Sindhu R, De Langhe, Ellen, Stagnaro, Chiara, Riccieri, Valeria, Schiopu, Elena, Silver, Richard M, Smith, Vanessa, Steen, Virginia, Stevens, Wendy, Szücs, Gabriella, Truchetet, Marie-Elise, Wosnitza, Melanie, Laapas, Kaisa, Kramer, Frank, and Khanna, Dinesh

Published
2023
Full Text
View/download PDF

28. Abatacept in Early Diffuse Cutaneous Systemic Sclerosis: Results of a Phase II Investigator‐Initiated, Multicenter, Double‐Blind, Randomized, Placebo‐Controlled Trial

Author

Khanna, Dinesh, Spino, Cathie, Johnson, Sindhu, Chung, Lorinda, Whitfield, Michael L, Denton, Christopher P, Berrocal, Veronica, Franks, Jennifer, Mehta, Bhavan, Molitor, Jerry, Steen, Virginia D, Lafyatis, Robert, Simms, Robert W, Gill, Anna, Kafaja, Suzanne, Frech, Tracy M, Hsu, Vivien, Domsic, Robyn T, Pope, Janet E, Gordon, Jessica K, Mayes, Maureen D, Schiopu, Elena, Young, Amber, Sandorfi, Nora, Park, Jane, Hant, Faye N, Bernstein, Elana J, Chatterjee, Soumya, Castelino, Flavia V, Ajam, Ali, Wang, Yue, Wood, Tammara, Allanore, Yannick, Matucci‐Cerinic, Marco, Distler, Oliver, Singer, Ora, Bush, Erica, Fox, David A, and Furst, Daniel E

Subjects
Biomedical and Clinical Sciences, Clinical Sciences, Brain Disorders, Clinical Research, Clinical Trials and Supportive Activities, 6.1 Pharmaceuticals, Evaluation of treatments and therapeutic interventions, Abatacept, Adult, Double-Blind Method, Female, Gene Expression, Gene Expression Profiling, Humans, Male, Middle Aged, Patient Reported Outcome Measures, Scleroderma, Diffuse, Sequence Analysis, RNA, Severity of Illness Index, Skin, Treatment Outcome, Tumor Necrosis Factor Inhibitors, Visual Analog Scale, Vital Capacity, Immunology, Public Health and Health Services, Arthritis & Rheumatology, Clinical sciences
Abstract

ObjectiveT cells play a key role in the pathogenesis of early systemic sclerosis. This study was undertaken to assess the safety and efficacy of abatacept in patients with diffuse cutaneous systemic sclerosis (dcSSc).MethodsIn this 12-month, randomized, double-blind, placebo-controlled trial, participants were randomized 1:1 to receive either subcutaneous abatacept 125 mg or matching placebo, stratified by duration of dcSSc. Escape therapy was allowed at 6 months for worsening disease. The coprimary end points were change in the modified Rodnan skin thickness score (MRSS) compared to baseline and safety over 12 months. Differences in longitudinal outcomes were assessed according to treatment using linear mixed models, with outcomes censored after initiation of escape therapy. Skin tissue obtained from participants at baseline was classified into intrinsic gene expression subsets.ResultsAmong 88 participants, the adjusted mean change in the MRSS at 12 months was -6.24 units for those receiving abatacept and -4.49 units for those receiving placebo, with an adjusted mean treatment difference of -1.75 units (P = 0.28). Outcomes for 2 secondary measures (Health Assessment Questionnaire disability index and a composite measure) were clinically and statistically significantly better with abatacept. The proportion of subjects in whom escape therapy was needed was higher in the placebo group relative to the abatacept group (36% versus 16%). In the inflammatory and normal-like skin gene expression subsets, decline in the MRSS over 12 months was clinically and significantly greater in the abatacept group versus the placebo group (P < 0.001 and P = 0.03, respectively). In the abatacept group, adverse events occurred in 35 participants versus 40 participants in the placebo group, including 2 deaths and 1 death, respectively.ConclusionIn this phase II trial, abatacept was well-tolerated, but change in the MRSS was not statistically significant. Secondary outcome measures, including gene expression subsets, showed evidence in support of abatacept. These data should be confirmed in a phase III trial.

Published
2020

30. Cohort Enrichment Strategies for Progressive Interstitial Lung Disease in Systemic Sclerosis From European Scleroderma Trials and Research

Author

Vacca, Alessandra, Giollo, Alessandro, Balbir-Gurman, Alexandra, Gheorghiu, Ana Maria, Marcoccia, Antonella, Herrick, Ariane, Radic, Mislav, Stamenkovic, Bojana, Anic, Branimir, Granel, Brigitte, Ribi, Camillo, Selmi, Carlo Francesco, Carlos de la Puente, Milano, de Souza Müller, Carolina, Denton, Christopher, Kayser, Cristiane, Tanaseanu, Cristina-Mihaela, Majewski, Dominik, Rimar, Doron, Krasowska, Dorota, Veale, Douglas, Walker, Ulrich, Kerzberg, Eduardo, Rezus, Elena, Zanatta, Elisabetta, Siegert, Elise, De Langhe, Ellen, Oksel, Fahrettin, Ingegnoli, Francesca, Cantatore, Francesco Paolo, Szücs, Gabriela, Cuomo, Giovanna, Seskute, Goda, Litinsky, VilniusIra, Castellví, Ivan, Morovic-Vergles, Jadranka, Sibilia, Jean, Henes, Jörg, Solanki, Kamal, Perdan-Pirkmajer, Katja, Herrmann, Kristine, Saketkoo, Lesley Ann, Stamp, Lisa, Mouthon, Luc, Salvador, Maria João, Pozzi, Maria Rosa, Üprus, Maria, Vanthuyne, Marie, Engelhart, Merete, Köhm, Michaela, Iudici, Michele, Inanc, Murat, Fathi, Nihal, Pamuk, Nuri, García de la Peña Lefebv, Paloma, Carreira, Patricia E., Bancel, Dominique Farge, Moroncini, Luca, Montecucco, C., Ancuta, Codrina, Sunderkötter, Cord, Müller-Ladner, Ulf, Rosato, Edoardo, Kucharz, Eugene J., Iannone, Florenzo, Del Galdo, Francesco, Poormoghim, Hadi, Kötter, Ina, Distler, Jörg, Cutolo, Maurizio, Tikly, Mohammed, Damjanov, Nemanja, Hunzelmann, Nicolas, Vlachoyiannopoulos, P., Hasler, Paul, Sarzi Puttini, Piercarlo, Wiland, Piotr, Becvar, Radim, Yavuz, Sule, Zdrojewski, Zbigniew, Pellerito, Raffaele, Foti, Rosario, Ionescu, Ruxandra Maria, Adler, Sabine, Kahl, Sarah, Moiseev, Sergey, Stebbings, Simon, Rednic, Simona, Negrini, Simone, Heitmann, Stefan, Ullman, Susanne, Agachi, Svetlana, Martin, Thierry, Schmeiser, Tim, Riccieri, Valeria, Smith, Vanessa, Bernardino, Vera, Ortiz-Santamaria, Vera, Hsu, Vivien M., Abdel Atty Mohamed, Walid Ahmed, Hoffmann-Vold, Anna-Maria, Brunborg, Cathrine, Airò, Paolo, Ananyeva, Lidia P., Czirják, László, Guiducci, Serena, Hachulla, Eric, Li, Mengtao, Mihai, Carina, Riemekasten, Gabriela, Sfikakis, Petros P., Valentini, Gabriele, Kowal-Bielecka, Otylia, Allanore, Yannick, and Distler, Oliver

Published
2023
Full Text
View/download PDF

31. MUC5B Promoter Variant and Rheumatoid Arthritis with Interstitial Lung Disease

Author

Juge, Pierre-Antoine, Lee, Joyce S, Ebstein, Esther, Furukawa, Hiroshi, Dobrinskikh, Evgenia, Gazal, Steven, Kannengiesser, Caroline, Ottaviani, Sébastien, Oka, Shomi, Tohma, Shigeto, Tsuchiya, Naoyuki, Rojas-Serrano, Jorge, González-Pérez, Montserrat I, Mejía, Mayra, Buendía-Roldán, Ivette, Falfán-Valencia, Ramcés, Ambrocio-Ortiz, Enrique, Manali, Effrosyni, Papiris, Spyros A, Karageorgas, Theofanis, Boumpas, Dimitrios, Antoniou, Katarina, van Moorsel, Coline HM, van der Vis, Joanne, de Man, Yaël A, Grutters, Jan C, Wang, Yaping, Borie, Raphaël, Wemeau-Stervinou, Lidwine, Wallaert, Benoît, Flipo, René-Marc, Nunes, Hilario, Valeyre, Dominique, Saidenberg-Kermanac’h, Nathalie, Boissier, Marie-Christophe, Marchand-Adam, Sylvain, Frazier, Aline, Richette, Pascal, Allanore, Yannick, Sibilia, Jean, Dromer, Claire, Richez, Christophe, Schaeverbeke, Thierry, Lioté, Huguette, Thabut, Gabriel, Nathan, Nadia, Amselem, Serge, Soubrier, Martin, Cottin, Vincent, Clément, Annick, Deane, Kevin, Walts, Avram D, Fingerlin, Tasha, Fischer, Aryeh, Ryu, Jay H, Matteson, Eric L, Niewold, Timothy B, Assayag, Deborah, Gross, Andrew, Wolters, Paul, Schwarz, Marvin I, Holers, Michael, Solomon, Joshua J, Doyle, Tracy, Rosas, Ivan O, Blauwendraat, Cornelis, Nalls, Mike A, Debray, Marie-Pierre, Boileau, Catherine, Crestani, Bruno, Schwartz, David A, and Dieudé, Philippe

Subjects
Epidemiology, Biomedical and Clinical Sciences, Health Sciences, Lung, Rare Diseases, Autoimmune Disease, Genetics, Clinical Research, Arthritis, Rheumatoid Arthritis, 2.1 Biological and endogenous factors, Aetiology, Inflammatory and immune system, Respiratory, Aged, Arthritis, Rheumatoid, Female, Gain of Function Mutation, Genetic Predisposition to Disease, Genotype, Humans, Idiopathic Pulmonary Fibrosis, Lung Diseases, Interstitial, Male, Middle Aged, Mucin-5B, Odds Ratio, Promoter Regions, Genetic, Medical and Health Sciences, General & Internal Medicine, Biomedical and clinical sciences, Health sciences
Abstract

BackgroundGiven the phenotypic similarities between rheumatoid arthritis (RA)-associated interstitial lung disease (ILD) (hereafter, RA-ILD) and idiopathic pulmonary fibrosis, we hypothesized that the strongest risk factor for the development of idiopathic pulmonary fibrosis, the gain-of-function MUC5B promoter variant rs35705950, would also contribute to the risk of ILD among patients with RA.MethodsUsing a discovery population and multiple validation populations, we tested the association of the MUC5B promoter variant rs35705950 in 620 patients with RA-ILD, 614 patients with RA without ILD, and 5448 unaffected controls.ResultsAnalysis of the discovery population revealed an association of the minor allele of the MUC5B promoter variant with RA-ILD when patients with RA-ILD were compared with unaffected controls (adjusted odds ratio, 3.8; 95% confidence interval [CI], 2.8 to 5.2; P=9.7×10-17). The MUC5B promoter variant was also significantly overrepresented among patients with RA-ILD, as compared with unaffected controls, in an analysis of the multiethnic case series (adjusted odds ratio, 5.5; 95% CI, 4.2 to 7.3; P=4.7×10-35) and in a combined analysis of the discovery population and the multiethnic case series (adjusted odds ratio, 4.7; 95% CI, 3.9 to 5.8; P=1.3×10-49). In addition, the MUC5B promoter variant was associated with an increased risk of ILD among patients with RA (adjusted odds ratio in combined analysis, 3.1; 95% CI, 1.8 to 5.4; P=7.4×10-5), particularly among those with evidence of usual interstitial pneumonia on high-resolution computed tomography (adjusted odds ratio in combined analysis, 6.1; 95% CI, 2.9 to 13.1; P=2.5×10-6). However, no significant association with the MUC5B promoter variant was observed for the diagnosis of RA alone.ConclusionsWe found that the MUC5B promoter variant was associated with RA-ILD and more specifically associated with evidence of usual interstitial pneumonia on imaging. (Funded by Société Française de Rhumatologie and others.).

Published
2018

32. Stratification in systemic sclerosis according to autoantibody status versus skin involvement: a study of the prospective EUSTAR cohort

Author

Matucci Cerinic, Marco, Walker, Ulrich, Iannone, Florenzo, Jordan, Suzana, Becvar, Radim, Kowal Bielecka, Otylia, Cutolo, Maurizio, Cuomo, Giovanna, Kedor, Claudia, Rednic, Simona, Avouac, Jérome, Vlachoyiannopoulos, P., Montecucco, C., Stork, Jiri, Inanc, Murat, Carreira, Patricia E., Novak, Srdan, Czirják, László, Iudici, Michele, Kucharz, Eugene J., Zanatta, Elisabetta, Perdan-Pirkmajer, Katja, Coleiro, Bernard, Moroncini, Gianluca, Farge Bancel, Dominique, Airò, Paolo, Hesselstrand, Roger, Radic, Mislav, Braun-Moscovici, Yolanda, Lo Monaco, Andrea, Hunzelmann, Nicolas, Pellerito, Raffaele, Giollo, Alessandro, Morovic-Vergles, Jadranka, Denton, Christopher, Vonk, Madelon, Damjanov, Nemanja, Henes, Jörg, Ortiz Santamaria, Vera, Heitmann, Stefan, Krasowska, Dorota, Hasler, Paul, Kohm, Michaela, Foeldvari, Ivan, Bajocchi, Gianluigi, Salvador, Maria João, Stamenkovic, Bojana, Selmi, Carlo Francesco, Tikly, Mohammed, Ananieva, Lidia P., Herrick, Ariane, Müller-Ladner, Ulf, De Palma, Raffaele, Engelhart, Merete, Szücs, Gabriela, Sobrino Grande, Cristina, Midtvedt, Øyvind, Launay, David, Riccieri, Valeria, Ionescu, Ruxandra Maria, Sha, Ami, Gheorghiu, Ana Maria, Sunderkötter, Cord, Ingegnoli, Francesca, Mouthon, Luc, Smith, Vanessa, Cantatore, Francesco Paolo, Ullman, Susanne, Alberto von Mühlen, Carlos, Pozzi, Maria Rosa, Eyerich, Kilian, Wiland, Piotr, Vanthuyne, Marie, Alegre-Sancho, Juan Jose, Herrmann, Kristine, De Langhe, Ellen, Anic, Branimir, Üprus, Maria, Yavuz, Sule, Granel, Brigitte, de Souza Müller, Carolina, Busquets, Joanna, Agachi, Svetlana, Stebbings, Simon, Mathieu, D'Alessandro, Sampaio-Barros, Percival D., Stamp, Lisa, Solanki, Kamal, Veale, Douglas, Loyo, Esthela, Li, Mengtao, Abdel Atty Mohamed, Walid Ahmed, Gigante, Antonietta, Oksel, Fahrettin, Tanaseanu, Cristina-Mihaela, Foti, Rosario, Ancuta, Codrina, Maurer, Britta, van Laar, Jacob, Kayser, Cristiane, Fathi, Nihal, García de la Peña Lefebvre, Paloma, Sibilia, Jean, Litinsky, Ira, Abignano, Giuseppina, Seskute, Goda, Saketkoo, Lesley Ann, Kerzberg, Eduardo, Bianchi, Washington, Castellví, Ivan, Limonta, Massimiliano, Rimar, Doron, Couto, Maura, Spertini, François, Marcoccia, Antonella, Kahl, Sarah, Hsu, Ivien M., Martin, Thierry, Moiseev, Sergey, Chung, Lorinda S., Schmeiser, Tim, Majewski, Dominik, Zdrojewski, Zbigniew, Martínez-Barrio, Julia, Bernardino, Vera, Sommerlatte, Sabine, Levy, Yair, Rezus, Elena, Nuri Pamuk, Omer, Sarzi Puttini, Piercarlo, Poormoghim, Hadi, Kötter, Ina, Gaches, Francis, Belloli, Laura, Sfikakis, Petros, Markus, Juliana, Feldman, Gary R, Ramazan, Ana-Maria, Scherer, H.U., Truchetet, Marie-Elise, Lescoat, Alain, Dagna, Lorenzo, van Laar, J.M., Rudnicka, Lidia, Oliveira, Susana, Atzeni, Fabiola, Kuwana, Masataka, Mekinian, Arsene, Martin, Mickaël, Tanaka, Yoshiya, Elhai, Muriel, Sritharan, Nanthara, Boubaya, Marouane, Balbir-Gurman, Alexandra, Siegert, Elise, Hachulla, Eric, de Vries-Bouwstra, Jeska, Riemekasten, Gabriela, Distler, Jörg H W, Rosato, Edoardo, Del Galdo, Francesco, Mendoza, Fabian A, Furst, Daniel E, de la Puente, Carlos, Hoffmann-Vold, Anna-Maria, Gabrielli, Armando, Distler, Oliver, Bloch-Queyrat, Coralie, and Allanore, Yannick

Published
2022
Full Text
View/download PDF

36. Complement component C4 structural variation and quantitative traits contribute to sex-biased vulnerability in systemic sclerosis

Author

Kerick, Martin, Acosta-Herrera, Marialbert, Simeón-Aznar, Carmen Pilar, Callejas, José Luis, Assassi, Shervin, Proudman, Susanna M., Nikpour, Mandana, Hunzelmann, Nicolas, Moroncini, Gianluca, de Vries-Bouwstra, Jeska K., Orozco, Gisela, Barton, Anne, Herrick, Ariane L., Terao, Chikashi, Allanore, Yannick, Fonseca, Carmen, Alarcón-Riquelme, Marta Eugenia, Radstake, Timothy R. D. J., Beretta, Lorenzo, Denton, Christopher P., Mayes, Maureen D., and Martin, Javier

Published
2022
Full Text
View/download PDF

40. Biomarker analysis from the phase 2b randomized placebo-controlled trial of riociguat in early diffuse cutaneous systemic sclerosis.

Author

Khanna, Dinesh, Kramer, Frank, Höfler, Josef, Ghadessi, Mercedeh, Sandner, Peter, Allanore, Yannick, Denton, Christopher P, Kuwana, Masataka, Matucci-Cerinic, Marco, Pope, Janet E, Atsumi, Tatsuya, Bečvář, Radim, Czirják, László, Langhe, Ellen De, Hachulla, Eric, Ishii, Tomonori, Ishikawa, Osamu, Johnson, Sindhu R, Riccieri, Valeria, and Schiopu, Elena

Subjects
HETEROCYCLIC compounds, BIOPSY, RADIOIMMUNOASSAY, RESEARCH funding, STATISTICAL sampling, POLYMERASE chain reaction, ENZYME-linked immunosorbent assay, TREATMENT effectiveness, RANDOMIZED controlled trials, SKIN, NUCLEOTIDES, IMMUNOHISTOCHEMISTRY, FIBROSIS, SYSTEMIC scleroderma, BIOMARKERS, VASCULAR cell adhesion molecule-1
Abstract

Objective To examine disease and target engagement biomarkers in the RISE-SSc trial of riociguat in early diffuse cutaneous systemic sclerosis and their potential to predict the response to treatment. Methods Patients were randomized to riociguat (n  = 60) or placebo (n  = 61) for 52 weeks. Skin biopsies and plasma/serum samples were obtained at baseline and week 14. Plasma cyclic guanosine monophosphate (cGMP) was assessed using radio-immunoassay. α-Smooth muscle actin (αSMA) and skin thickness were determined by immunohistochemistry, mRNA markers of fibrosis by qRT-PCR in skin biopsies, and serum CXC motif chemokine ligand 4 (CXCL-4) and soluble platelet endothelial cell adhesion molecule-1 (sPECAM-1) by enzyme-linked immunosorbent assay. Results By week 14, cGMP increased by 94 (78)% with riociguat and 10 (39)% with placebo (P  < 0.001, riociguat vs placebo). Serum sPECAM-1 and CXCL-4 decreased with riociguat vs placebo (P  = 0.004 and P  = 0.008, respectively). There were no differences in skin collagen markers between the two groups. Higher baseline serum sPECAM-1 or the detection of αSMA-positive cells in baseline skin biopsies was associated with a larger reduction of modified Rodnan skin score from baseline at week 52 with riociguat vs placebo (interaction P -values 0.004 and 0.02, respectively). Conclusion Plasma cGMP increased with riociguat, suggesting engagement with the nitric oxide–soluble guanylate cyclase–cGMP pathway. Riociguat was associated with a significant reduction in sPECAM-1 (an angiogenic biomarker) vs placebo. Elevated sPECAM-1 and the presence of αSMA-positive skin cells may help to identify patients who could benefit from riociguat in terms of skin fibrosis. Trial registration Clinicaltrials.gov, NCT02283762. [ABSTRACT FROM AUTHOR]

Published
2024
Full Text
View/download PDF

42. Arrhythmias

Author

Allanore, Yannick, Meune, Christophe, Matucci-Cerinic, Marco, editor, and Denton, Christopher P., editor

Published
2021
Full Text
View/download PDF

44. Progression of patients with Raynaud's phenomenon to systemic sclerosis: a five-year analysis of the European Scleroderma Trial and Research group multicentre, longitudinal registry study for Very Early Diagnosis of Systemic Sclerosis (VEDOSS)

Author

Bellando-Randone, Silvia, Del Galdo, Francesco, Lepri, Gemma, Minier, Tunde, Huscher, Dörte, Furst, Daniel E, Allanore, Yannick, Distler, Oliver, Czirják, László, Bruni, Cosimo, Guiducci, Serena, Avouac, Jerome, Cutolo, Maurizio, Smith, Vanessa, and Matucci-Cerinic, Marco

Published
2021
Full Text
View/download PDF

46. Attitudes and barriers to pulmonary arterial hypertension screening in systemic sclerosis patients: A survey of UK-based rheumatologists

Author

Álvarez-Hernández, María Paula, primary, Allanore, Yannick, additional, Andrade, Ivo, additional, Buch, Maya H, additional, Coghlan, Gerry, additional, Del Galdo, Francesco, additional, Denton, Christopher P, additional, Khanna, Dinesh, additional, Kiely, David G, additional, Pauling, John D, additional, Ramjug, Sheila, additional, and Hughes, Michael, additional

Published
2024
Full Text
View/download PDF

48. COVID-19 outcomes in patients with inflammatory rheumatic and musculoskeletal diseases treated with rituximab: a cohort study

Author

Aeschlimann, Florence, Agard, Christian, Ait-Abdallah, Nassim, Albert, Jean-David, Alcais, Didier, Allain, Jean-Sébastien, Allanore, Yannick, Amador-Borreiro, Blanca, Amoura, Zahir, Andre, Emma, Arbault, Anaïs, Arlet, Jean-Benoît, Arnaud, Laurent, Arniaud, Denis, Arty-Hue, Herliette, Atlan, Lucie, Audemard-Verger, Alexandra, Audoin-Pajot, Christine, Audren, Victor, Bach-Bunner, Maxime, Bacquet-Deschryver, Hélène, Bader-Meunier, Brigitte, Balandraud, Nathalie, Balblanc, Jean-Charles, Bally, Stéphane, Banal, Frédéric, Barbery, Pierre, Barnetche, Thomas, Barrelet, Audre, Basch, André, Baumier, Vincent, Bayer, Guillaume, Bayle, Sophie, Beauvais, Catherine, Beinat, Rudie, Belin, Véronique, Belkhir, Rakiba, Benainous, Ruben, Belot, Alexandre, Benammar, Mohammed, Benhamou, Mathilde, Benhamou, Ygal, Benmansour, Ahmed, Bennet, Pascal, Bernoux-Manat, Brigitte, Berthet, Elise, Berthoux, Emilie, Bertolini, Ewa, Bigot, Adrien, Bisson-Vaivre, Aurélia, Blaison, Gilles, Bolla, Gilles, Bonidan, Olivier, Bonnet, Christine, Borie, Raphaël, Bossert, Marie, Boudou, Laurence, Bouhour, Françoise, Bouiller, Kévin, Bouldoires, Bastien, Boussoualim, Karima, Bouvard, Eric, Brondino, Regine, Buchlin, Pierre, Cabantous, Laurence, Cacoub, Patrice, Cadiou, Simon, Carteni, Maurizio, Carbasse, Aurélia, Castel, Brice, Cathebras, Pascal, Caumont, Hervé, Celant, Annalisa, Chaigne, Benjamin, Chaillous, Benoît, Champy, Romuald, Charcot, Agnès, Charles, Pierre, Charlot-Lambrecht, Isabelle, Charpin, Caroline, Chatelus, Emmanuel, Chaudier, Bernard, Chertok, Pascale, Chevalier, Xavier, Chevreau, Maxime, Chotard, Emilie, Chu Miow Lin, Delphine, Clavel, Gaëlle, Clavel-Osorio, Cyril, Cohen, Fleur, Cohen, Gregory, Colette-Cedoz, Marie-Eve, Collercandy, Nived, Colombey, Antoine, Comarmond, Chloé, Combe, Bernard, Comparon, Céline, Constant, Elodie, Coquerelle, Pascal, Corli, Justine, Corre, Clémence, Costedoat-Chalumeau, Nathalie, Couret, Marie, Courvoisier, Natacha, Coury-Lucas, Fabienne, Coutarel, Cécile, Coutier, Fabrice, Damade, Richard, Daver-Malaterre, Laurence, Dehimat, Sarahe, Delahousse, Michel, Barrois-Delattre, Emilie, Denarie, Delphine, Deprouw, Camille, Dernis, Emanuelle, Deroux, Alban, Desbarbieux, Renaud, Descamps, Elise, Deslandre, Chantal, Desmurs, Marie, Despaux, Jacques, Desplats, Marie, Detree, Frédérick, Devauchelle-Pensec, Valérie, Dhote, Robin, Dieude, Philippe, Dieudonne, Yannick, Diot, Elisabeth, Direz, Guillaume, Djeddi, Djamal-Dine, Douvier, Sarah, Drouet, Béatrice, Drumez, Elodie, Duc, Catherine, Ducornet, Angélique, Dufauret-Lombard, Carine, Duhamel, Alain, Dumaine, Cécile, Dumel, Anne-Elisabeth, Dumoulin-Richez, Chantal, Duquesne, Agnès, Durand, Géraldine, Durandin-Truffinet, Mariane, Duret, Pierre-Marie, Duval, Maïka, Ebbo, Mikaël, Ebstein, Esther, Economu-Dubosc, Andra, Emilie, Stéphanie, Euvrard, Romain, Evon, Philippe, Fabre, Sylvie, Fagedet, Dorothée, Farhat, Meryem, Fauconier, Marion, Fechtenbaum, Jacques, Felten, Renaud, Fernandes, Fanny, Ferreira-Maldent, Nicole, Feurer, Elodie, Fichet, Amandine, Flaisler, Françoise, Florens, Nans, Foltz, Violaine, Fontanges, Elisabeth, Foret, Jennifer, Fougerousse, Anne-Claire, Fouque-Aubert, Anne, Foutrier-Morello, Catherine, Francois-Pradier, Hélène, Frantzen, Léa, Fritz, Pierre, Froissart, Antoine, Fulpin, Jean, Fuzibet, Piera, Gaches, Francis, Gagneux-Lemoussu, Laurence, Penhoat-Gahier, Mélanie, Galland, Joris, Gandjbakhch, Frédérique, Garnier, Nicole, Garraud, Thomas, Garrot, Jean-François, Gastaldi, Romain, Gaud-Listrat, Véronique, Gauthier-Prieur, Maud, Georgescu, Dana, Gerard, Nathalie, Gervais, Elisabeth, Gibert, Christelle, Gibert, Eric, Gill, Ghislaine, Gillard, Jérôme, Gilson, Mélanie, Gimonnet, Pauline, Giraudet-Le Quintrec, Jeanine-Sophie, Giraud-Morelet, Aude, Glace, Baptiste, Glanowski, Camille, Godeau, Bertrand, Gombert, Bruno, Gonnet-Gracia, Camille, Goulenok, Tiphaine, Goupille, Philippe, Gourmelen, Olivier, Govindaraju-Audouard, Sophie, Grados, Franck, Grall-Lerosey, Martine, Grardel, Bruno, Grasland, Anne, Grateau, Gilles, Groza, Monica, Guillaud, Constance, Guillaume, Séverine, Guillibert, Caroline, Guillot, Xavier, Guilpain, Philippe, Gury, Aline, Guyot, Marie-Hélène, Hacquard-Bouder, Cécile, Havard, Marie-Noelle, Hellier, Jean-Pierre, Hennequin, Pascal, Henriot, Basile, Henry, Julien, Hentgen, Véronique, Hermet, Marion, Herasse, Muriel, Hernandez, Julie, Hie, Miguel, Hilliquin, Pascal, Hinschberger, Olivier, Hittinger-Roux, Ambre, Holubar, Jan, Hudry, Christophe, Huguenel, Serge, Jaccard, Clara, Jacquemier, Jean-Michel, Jamard, Bénédicte, Jan, Catherine, Jean, Sylvie, Jouvray, Mathieu, Juge, Pierre-Antoine, Juillard, Laurent, Jullien, Denis, Kabala, Anna, Kabchou, Abdelkrim, Karkowski, Ludovic, Karman, Françoise, Kemiche, Farid, Keraen, Jérémy, Kieffer, Pierre, Kone-Paut, Isabelle, Koreichi, Abdeldajallil, Kostine, Marie, La Batide Alanore, Sylvain, Lafforgue, Pierre, Lahalle, Sophie, Lambert, Marc, Lambrecht, Isabelle, Lanot, Sylvain, Lanteri, Aurélia, Larbre, Jean-Paul, Latourte, Augustin, Lavigne, Christian, Le Guen Guegan, Sophie, Le Guenno, Guillaume, Leguy, Diane, Lebrun, Agnès, Ledoult, Emmanuel, Legoupil, Nathalie, Legrand, Erick, Lejeune, Charlotte, Leloire, Olivier, Leroux, Christophe, Leroy, Rémi, Leroy-Gouix, Marie, Leturcq, Tifenn, Leurs, Amélie, Leveque-Michaud, Céline, Limbach, François-Xavier, Liote, Frédéric, Lohse, Anne, Lozac'h, Pierre, Lucas, Virginie, Madelon, Aurélie, Magy-Bertrand, Nadine, Mahevas, Matthieu, Maillard, Hélène, Maillet, Thibault, Malochet-Guinamand, Sandrine, Mangon, Quentin, Marchou-Lopez, Sylvie, Margarit, Nathalie, Marhadour, Thierry, Mariette, Xavier, Martin, Claire, Mathian, Alexis, Maurier, François, Maury, Frédéric, Mazet-Guillaume, Betty, Mazouyez, Arnaud, Mazyad, Hassan, Mehsen-Cetre, Nadia, Meinzer, Ulrich, Melki, Isabelle, Messer, Laurent, Miceli, Corinne, Michaud, Martin, Michel, Catherine, Michel, Matthias, Michon, Mathilde, Milesi-Lecat, Anne-Marie, Molto, Anna, Moly, Marie, Moranne, Olivier, Morel, Gautier, Morel, Hugo, Morel, Jacques, Morin, Franck, Moulinier, Laurence, Moulis, Guillaume, Moura, Bertrand, Nguyen, Minh, Nicolas-Vullierme, Sabine, Nielly, Hubert, Nocturne, Gaétane, Nottez, Aurore, Ollagnon, Henri-Olivier, Pacaud-Vitoux, Isabelle, Pagnier, Anne, Paris, Caroline, Parrot, Antoine, Pascart, Tristan, Pascaud-Mansour, Yasmina, Paulin, Lætitia, Pavy, Stephan, Perard, Laurent, Pers, Yves-Marie, Pha, Micheline, Pichon, Maud, Pierreisnard, Audrey, Pizana, Gabrielle, Poignant, Sylvaine, Poix, Elsa, Portier, Agnès, Poulet, Antoine, Plassard, Samira, Pugnet, Grégory, Puyraimond-Zemmour, Déborah, Quartier-Dit-Maire, Pierre, Quenet, Marion, Queyrel, Viviane, Raffray, Loïc, Remy, Philippe, Renard, Myriam, Rene, Jessica, Revuz, Sabine, Rey, Bénédicte, Richard-Colmant, Gaëlle, Riviere, Etienne, Riviere, Sébastien, Robin, Sophie, Rohmer, Julien, Roitg, Isabelle, Romier, Mélanie, Rolland, Michel, Roriz, Mélanie, Rosenberg, Carole, Rossi, Linda, Roth, Olivier, Rouidi, Sid-Ahmed, Roumier, Mathilde, Rousiere, Mickaël, Rousselin, Clémentine, Rouviere, Bénédicte, Roux, Christian, Roux, Fabienne, Roux, Marielle, Roux, Nicolas, Rouzaud, Diane, Rozenberg, Sylvie, Sacco, Isabelle, Sadji, Fatiha, Sailler, Laurent, Salliot, Carine, Salmon, Jean-Hugues, Saraux, Alain, Schmidt, Jean, Seguier, Julie, Sellam, Jérémie, Senbel, Eric, Sene, Thomas, Senet, Patricia, Seve, Pascal, Sicaud, Aurélie, Smets, Perrine, Sobanski, Vincent, Sordet, Christelle, Sornay-Rendu, Elisabeth, Souchaud-Debouverie, Odile, Sparsa, Lætitia, Spielmann, Lionel, Steib, Sarah, Stavris, Chloé, Straus, Catherine, Strotz, Victor, Szafors, Paulina, Taffignon-Clave, Séverine, Simoens, Justine, Theillac, Claire, Tenenbaum, Nora, Thomachot, Benoît, Tieulie, Nathalie, Tiriau, Soizic, Tison, Alice, Toussirot, Eric, Trefond, Ludovic, Trijau, Sophie, Trouillier, Sébastien, Trouvin, Anne-Priscille, Truchetet, Marie-Elise, Ulrich, Marc, Vaquier, Jacques, Veillard, Eric, Veillon, Laurent, Vial, Guillaume, Viallard, Jean-François, Victor, Judith, Vidon, Claire, Vidon, Mathias, Vigne, Camille, Virone, Alexandre, Warzocha, Ursula, Wendling, Daniel, Werle, Claude, Wibaux, Cécile, Willems, Alexandra, Wisniewski, Michel, Woessner, Juliette, Xerri-Campano, Bernadette, Avouac, Jérôme, Hachulla, Eric, Seror, Raphaèle, Georgin-Lavialle, Sophie, El Mahou, Soumaya, Pertuiset, Edouard, Pham, Thao, Marotte, Hubert, Servettaz, Amélie, Domont, Fanny, Chazerain, Pascal, Devaux, Mathilde, Claudepierre, Pascal, Langlois, Vincent, Mekinian, Arsène, Maria, Alexandre Thibault Jacques, Banneville, Béatrice, Fautrel, Bruno, Pouchot, Jacques, Thomas, Thierry, Flipo, René-Marc, and Richez, Christophe

Published
2021
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results